Tilray Medical, a division of Tilray Brands, Inc., made a significant move in the Australian medical cannabis market on Wednesday. The company announced the launch of Redecan EU-GMP certified medical cannabis products, expanding its offerings for patients seeking alternative therapeutic solutions.
Two Redecan products, Redecan PC THC28 Purple Churro and Redecan SA THC28 Space Age Cake, are now available for medical cannabis patients in Australia. This expansion signifies Tilray’s commitment to providing a diverse range of high-quality medical cannabis options for patients and healthcare practitioners.
Denise Faltischek, Chief Strategy Officer and Head of International at Tilray Brands, expressed enthusiasm for the launch. “The launch of Redecan further expands our medical cannabis portfolios alongside our current Tilray and Broken Coast offerings, as we continue our mission of empowering patients and healthcare practitioners to find the optimal therapeutic solutions,” she stated.
Jonathan Trodden, Director at Tilray Medical Australia, echoed Faltischek’s sentiments, emphasizing the company’s dedication to patient access and quality. “We are proud to launch Redecan in Australia and further strengthen our ongoing commitment to providing patients with a consistent, accessible supply of premium quality medical cannabis to choose from.”
Tilray’s presence in Australia has been growing steadily. In 2022, the company introduced a new medical cannabis e-learning platform designed for healthcare providers, highlighting the importance of comprehensive education about the benefits of medical cannabis use. This initiative built upon Tilray’s successful medical cannabis workshops conducted across Australia and New Zealand in 2021, where hundreds of healthcare practitioners received valuable training.
Tilray’s shares experienced a positive response to the news, trading 0.51% higher at $1.8193 per share during the pre-market session on Wednesday morning.
